ClinOleic (Baxter Healthcare, Deerfield, IL, USA)
Phase 1UNKNOWN 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nutritional Supplement Toxicity
Conditions
Nutritional Supplement Toxicity
Trial Timeline
Jul 1, 2017 → Jun 30, 2020
NCT ID
NCT04051840About ClinOleic (Baxter Healthcare, Deerfield, IL, USA)
ClinOleic (Baxter Healthcare, Deerfield, IL, USA) is a phase 1 stage product being developed by Baxter for Nutritional Supplement Toxicity. The current trial status is unknown. This product is registered under clinical trial identifier NCT04051840. Target conditions include Nutritional Supplement Toxicity.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04051840 | Phase 1 | UNKNOWN |
Competing Products
2 competing products in Nutritional Supplement Toxicity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| rasburicase (SR29142) | Sanofi | Phase 2 | 51 |
| stannsoporfin | Mallinckrodt Pharmaceuticals | Phase 3 | 69 |